Pu YS - Search Results

1

Clinical and pathological data of 10 malignant pheochromocytomas: long-term follow up in a single institute.

Huang KH, Chung SD, Chen SC, Chueh SC, Pu YS, Lai MK, Lin WC. Huang KH, et al. Among authors: pu ys. Int J Urol. 2007 Mar;14(3):181-5. doi: 10.1111/j.1442-2042.2007.01687.x. Int J Urol. 2007. PMID: 17430251

2

Cytotoxicity of arsenic trioxide to transitional carcinoma cells.

Pu YS, Hour TC, Chen J, Huang CY, Guan JY, Lu SH. Pu YS, et al. Urology. 2002 Aug;60(2):346-50. doi: 10.1016/s0090-4295(02)01699-0. Urology. 2002. PMID: 12137851

3

Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells.

Pu YS, Hour TC, Chuang SE, Cheng AL, Lai MK, Kuo ML. Pu YS, et al. Prostate. 2004 Jul 1;60(2):120-9. doi: 10.1002/pros.20057. Prostate. 2004. PMID: 15162378

4

Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity.

Lin CC, Hsu CH, Huang CY, Cheng AL, Chen J, Vogelzang NJ, Pu YS. Lin CC, et al. Among authors: pu ys. Cancer. 2006 Mar 15;106(6):1269-75. doi: 10.1002/cncr.21738. Cancer. 2006. PMID: 16470604 Free article. Clinical Trial.

5

Primary amyloidosis of the urinary bladder.

Huang CY, Shun CT, Huang KH, Chen J, Pu YS. Huang CY, et al. Among authors: pu ys. J Formos Med Assoc. 2006 Feb;105(2):164-7. doi: 10.1016/S0929-6646(09)60339-9. J Formos Med Assoc. 2006. PMID: 16477338 Free article.

6

High incidence of and risk factors for metachronous bilateral upper tract urothelial carcinoma in Taiwan.

Huang PC, Huang CY, Huang SW, Lai MK, Yu HJ, Chen J, Pu YS. Huang PC, et al. Among authors: pu ys. Int J Urol. 2006 Jul;13(7):864-9. doi: 10.1111/j.1442-2042.2006.01429.x. Int J Urol. 2006. PMID: 16882044

7

Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.

Lin CC, Hsu CH, Huang CY, Cheng AL, Vogelzang NJ, Pu YS. Lin CC, et al. Among authors: pu ys. J Urol. 2007 Jan;177(1):84-9; discussion 89. doi: 10.1016/j.juro.2006.08.058. J Urol. 2007. PMID: 17162009 Clinical Trial.

8

Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study.

Lin CC, Hsu CH, Huang CY, Keng HY, Tsai YC, Huang KH, Cheng AL, Pu YS. Lin CC, et al. Among authors: pu ys. Anticancer Drugs. 2007 Apr;18(4):487-91. doi: 10.1097/CAD.0b013e3280126603. Anticancer Drugs. 2007. PMID: 17351402 Clinical Trial.

9

Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.

Lin CC, Hsu CH, Huang CY, Tsai YC, Huang KH, Cheng AL, Pu YS. Lin CC, et al. Among authors: pu ys. Urology. 2007 Mar;69(3):479-84. doi: 10.1016/j.urology.2006.12.010. Urology. 2007. PMID: 17382149 Clinical Trial.

10

Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer.

Chen CH, Shun CT, Huang KH, Huang CY, Tsai YC, Yu HJ, Pu YS. Chen CH, et al. Among authors: pu ys. BJU Int. 2007 Aug;100(2):281-6; discussion 286. doi: 10.1111/j.1464-410X.2007.06873.x. Epub 2007 Apr 5. BJU Int. 2007. PMID: 17419696

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

265 results

Search Page

Filters